<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zhps</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал прикладной спектроскопии</journal-title><trans-title-group xml:lang="en"><trans-title>Zhurnal Prikladnoii Spektroskopii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0514-7506</issn><publisher><publisher-name>B. I. Stepanov Institute of Physics of the National Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">zhps-2380</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АННОТАЦИИ АНГЛОЯЗЫЧНЫХ СТАТЕЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ABSTRACTS ENGLISH-LANGUAGE ARTICLES</subject></subj-group></article-categories><title-group><article-title>Разработка и валидация метода ближней ИК-спектроскопии для количественного определения фидаксомицина в таблетированной форме</article-title><trans-title-group xml:lang="en"><trans-title>Development and Validation of a Near-Infrared Spectroscopy Method for Quantification of the Fidaxomicin in Tablets</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гагаре</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Gagare</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нью-Панвел</p></bio><bio xml:lang="en"><p>Sunita Sunil Gagare</p><p>New Panvel</p></bio><email xlink:type="simple">sunita.gagare19@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бандгар</surname><given-names>П. Дж.</given-names></name><name name-style="western" xml:lang="en"><surname>Bandgar</surname><given-names>P. Ja.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нью-Панвел</p></bio><bio xml:lang="en"><p>Priyanka Jagannath Bandgar</p><p>New Panvel</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джайн</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Jain</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нью-Панвел</p></bio><bio xml:lang="en"><p>Ashish Suresh Jain</p><p>New Panvel</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Фармацевтический колледж и научно-исследовательский центр Шри Д. Д. Виспуте</institution><country>Индия</country></aff><aff xml:lang="en"><institution>Shri D. D. Vispute College of Pharmacy &amp; Research Center</institution><country>India</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>10</day><month>09</month><year>2026</year></pub-date><volume>93</volume><issue>3</issue><fpage>442</fpage><lpage>7</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гагаре С.С., Бандгар П.Д., Джайн А.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Гагаре С.С., Бандгар П.Д., Джайн А.С.</copyright-holder><copyright-holder xml:lang="en">Gagare S.S., Bandgar P.J., Jain A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://zhps.ejournal.by/jour/article/view/2380">https://zhps.ejournal.by/jour/article/view/2380</self-uri><abstract><p>   Разработан и валидирован новый аналитический метод с использованием отражательной ближней ИК-спектроскопии (NIRS) в сочетании с многомерной калибровкой методом частичных наименьших квадратов (PLS) для определения фидаксомицина в таблетированных препаратах. Метод диффузной отражательной спектроскопии в ближнем ИК-диапазоне в режиме отражения — универсальный, используется для анализа оптических свойств материалов путем сочетания измерений отражения и пропускания. Для установления взаимосвязи между максимумами ИК-спектра и концентрациями фидаксомицина в известном стандарте использована регрессия методом частичных наименьших квадратов. Оценены коэффициент корреляции (R2), среднеквадратичная ошибка перекрестной проверки (RMSECV), смещение и относительная процентная разница (RPD). Показатели качества, в том числе линейность, точность, правильность, устойчивость, селективность и аналитическая чувствительность, оценены в соответствии с рекомендациями ICH. Эффективность модели R2 = 99.9 указывает на отличную прогностическую способность; RMSECV = 4.19 отражает низкую ошибку прогнозирования; смещение 0.639; RPD = 31.3. Предложенный метод NIR-PLS является жизнеспособной альтернативой ВЭЖХ для количественного определения фидаксомицина, имеет преимущества в скорости, простоте, стоимости и экологической устойчивости. В соответствии с рекомендациями ICH метод демонстрирует надежность и применимость для рутинного фармацевтического контроля качества.</p></abstract><trans-abstract xml:lang="en"><p>   A novel analytical method using reflectance NIRS combined with PLS multivariate calibration to determine fidaxomicin in tablet formulations has been developed and validated. NIR diffuse reflectance spectroscopy in reflectance mode is a versatile technique used for analyzing the optical properties of materials by combining reflection and transmission measurements. Partial least squares regression was used to establish the relationship between the IR peaks and fidaxomicin concentrations in a known standard. Metrics evaluated included correlation coefficient (R2), root mean squared error of cross-validation (RMSECV), bias, and relative percentage difference (RPD). Figures of merit, including linearity, precision, accuracy, ruggedness, selectivity, and analytical sensitivity, were assessed in accordance with ICH guidelines. Model performance was as follows: R2 = 99.9, indicating excellent predictive capability; RMSECV = 4.19, reflecting low prediction error; bias 0.639; RPD 31.3. The method was validated as linear, precise, accurate, and rugged. The proposed NIR-PLS method is a viable alternative to HPLC for fidaxomicin quantification, offering advantages in speed, simplicity, cost, and environmental sustainability. By adhering to ICH guidelines, the method demonstrated reliability and applicability for routine pharmaceutical quality control.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ближняя ИК-спектроскопия</kwd><kwd>аналитический метод</kwd><kwd>статистический метод</kwd><kwd>количественное определение</kwd><kwd>валидация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>near-infrared spectroscopy</kwd><kwd>analytical method</kwd><kwd>statistical method</kwd><kwd>quantification</kwd><kwd>validation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Это исследование не получало каких-либо конкретных грантов от каких-либо финансирующих учреждений в государственном, коммерческом или некоммерческом секторах</funding-statement><funding-statement xml:lang="en">This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">K. V. Kumar, J. Iran. Chem. Soc., 19, 785–792 (2022), doi: 10.1007/s13738-021-02343-4.</mixed-citation><mixed-citation xml:lang="en">K. V. Kumar, J. Iran. Chem. Soc., 19, 785–792 (2022), doi: 10.1007/s13738-021-02343-4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">M. Blanco, M. Alcalá, Eur. J. Pharm. Sci., 27, 280–286 (2006), doi: 10.1016/j.ejps.2005.10.008.</mixed-citation><mixed-citation xml:lang="en">M. Blanco, M. Alcalá, Eur. J. Pharm. Sci., 27, 280–286 (2006), doi: 10.1016/j.ejps.2005.10.008.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">P.-F. Chavez, Talanta, 144, 1352–1359 (2015), doi: 10.1016/j.talanta.2015.08.018.</mixed-citation><mixed-citation xml:lang="en">P.-F. Chavez, Talanta, 144, 1352–1359 (2015), doi: 10.1016/j.talanta.2015.08.018.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">International Conference on Harmonization (ICH). (2005). Validation of Analytical Procedures: Text and Methodology, Q2(R1), https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf [accessed 19 Mar 2025].</mixed-citation><mixed-citation xml:lang="en">International Conference on Harmonization (ICH). (2005). Validation of Analytical Procedures: Text and Methodology, Q2(R1), https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf [accessed 19 Mar 2025].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">M. A. M. Silva, Talanta, 89, 342–351 (2012), doi: 10.1016/j.talanta.2011.12.039.</mixed-citation><mixed-citation xml:lang="en">M. A. M. Silva, Talanta, 89, 342–351 (2012), doi: 10.1016/j.talanta.2011.12.039.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">M. Blanco, Fres. J. Anal. Chem., 368, 534–539 (2000), doi: 10.1007/s002160000506.</mixed-citation><mixed-citation xml:lang="en">M. Blanco, Fres. J. Anal. Chem., 368, 534–539 (2000), doi: 10.1007/s002160000506.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">C. De Bleye, J. Pharm. Biomed. Anal., 69, 125–132 (2012), doi: 10.1016/j.jpba.2012.02.003.</mixed-citation><mixed-citation xml:lang="en">C. De Bleye, J. Pharm. Biomed. Anal., 69, 125–132 (2012), doi: 10.1016/j.jpba.2012.02.003.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
